Back to top
Top

["Allergy, Intolerance": "Beta Blocker Therapy Ingredient"]

Performance/Reporting Period
2022
Value Set Description from VSAC
Clinical Focus: The purpose of this value set is to represent concepts for medications containing ingredients for beta blocker therapy.
Data Element Scope: This value set may use a model element related to Allergy/Intolerance.
Inclusion Criteria: Includes concepts that represent an allergy or intolerance for prescribable beta blockers.
Exclusion Criteria: No exclusions.

Constrained to codes in the Allergy, Intolerance: Beta Blocker Therapy Ingredient value set (2.16.840.1.113883.3.526.3.1493)

QDM Datatype and Definition (QDM Version 5.5 Guidance Update)

"Allergy Intolerance"

Data elements that meet criteria using this datatype should document the allergy or intolerance and its corresponding value set.

Timing:

  • The prevalence period references the time from the onset date to the abatement date. Often an abatement date is not present as allergy or intolerance is ongoing.
  • The author dateTime references the recorded time.
QDM Attributes

prevalencePeriod

Prevalance Period is the time from onset dateTime to abatement dateTime.
Last Updated: Jul 08, 2021